Single versus double hamstring tendon graft in anterior cruciate ligament reconstruction in the paediatric patient: a single-blind randomised controlled trial study protocol

David Bade,1,2 Garrett Malayko,1 Liam Johnson,1 Kylie Bradford,1 Tristan Reddan,1,2 Chris Stockton,3 Kieran Frawley,3 Teresa Phillips,1 David Saxby,2 Robert S Ware,1,4 Joshua Byrnes,5 Christopher P Carty1,2

ABSTRACT

Introduction There is currently no clear indication in the literature regarding a single or double hamstring tendon (single bundle) autograft for anterior cruciate ligament (ACL) reconstruction in the paediatric patient. The primary aim of this single blind randomised controlled trial is to determine whether a single or double hamstring tendon graft ACLR leads to superior clinical outcomes postsurgery in paediatric patients with ACL injury.

Methods and analysis Single site, prospective, single blind, randomised controlled trial with two parallel treatment arms. 100 patients aged 10–18 years who present with an isolated ACL tear and meniscal injury, verified on MRI, will be randomly allocated to one of the two surgical groups. The primary outcomes will be side-to-side difference in anterior tibial translation and graft failure incidence 12 months postsurgery. Primary and secondary outcomes will also be assessed at 2-year and 5-year postsurgery.

Ethics and dissemination Results will be presented in peer-reviewed journals and at international conferences and disseminated to participants and healthcare professionals via newsletters and hospital presentations. This study is approved by the Children’s Health Queensland Hospital and Health Service Human Research Ethics committee.

Trial registration number ACTRN12620001170910p; Australian New Zealand Clinical Trials Registry.

BACKGROUND

The diagnosis of anterior cruciate ligament (ACL) injury and reconstruction (ACLR) in skeletally immature patients is climbing at a rate significantly higher than adults.1 The increased incidence has been attributed to several factors including a rise in competitive sport participation, decreased incidental activity, increased clinical awareness of a potential for ACL tear in this population, more comprehensive diagnosis and evaluation with MRI and a shift in clinical practice to provide early intervention.2–5 Most ACL injuries are non-contact with the mechanism and/or consequence of injury a combination of tibiofemoral joint external rotation and valgus.6 Historically, conservative management of ACL tears was the preferred clinical method in skeletally immature patients with bracing and modification of activities until skeletal maturity when ACLR could be safely performed.1 7 The weight of available evidence now supports reconstruction over conservative management with minimal complications8–12 and there is a growing body of evidence indicating that delayed ACL reconstruction increases the
risk of secondary articular injuries including irreparable meniscal tears, meniscal tears and chondral injuries in paediatric patients. Nonetheless, evidence regarding the ideal surgical technique for the skeletally immature patient is still lacking. Indeed, ACLR techniques that aim to reproduce the native ACL morphology with emphasis on graft placement within the native femoral footprint is well supported in the adult literature; however, the risk in the skeletally immature patient is the potential for growth disturbance. Restoration of native anatomical laxity is a fundamental principle in ACLR. Indeed, suboptimal postoperative laxity may alter knee loading and have long-term consequences for the patient (ie, development of osteoarthritis). In studies of adults, positive rotational laxity results have been reported for double-bundle techniques, which use two smaller grafts to replicate the morphology of the native ACL. Nonetheless, a combined physeal-sparing, double-bundle method has led to less promising mid-term results in skeletally immature patients. Regarding graft selection, there are a number of options including allografts, quadriceps tendon autografts, hamstring tendon autografts, patellar tendon autografts, and iliotibial band autografts. Nonetheless, there remains a lack of evidence surrounding the optimal graft selection when considering functional outcomes, failure rates and patient satisfaction for paediatric ACLR.

At our institution, single bundle hamstring autografts are preferred for the skeletally immature patient using a single (semitendinosus tendon) or double (semitendinosus plus gracilis tendon) hamstring tendon graft. We acknowledge that hamstring tendon harvest is not without limitation or comparison (ie, quadriceps tendon, iliotibial band, various soft tissue allografts). In studies of adults, harvest of the semitendinosus and gracilis tendons has led to postoperative donor muscle atrophy as well as proximal retraction of the musculotendinous junction. This retraction is believed to occur until the regenerated tendon reaches an attachment site, which may take longer than 2 years, or it may not occur at all. These changes in donor muscle-tendon properties and impaired capacity to transmit force to the skeleton after medial hamstring harvest might be expected to contribute to the knee muscle weakness that has been reported in flexion and internal tibial rotation at up to 2 years after surgery. In a study of muscle and tendon morphology of 20 adult patients who underwent ACLR with hamstring autograft, Konrath et al found only 35% of patients showed regeneration of both the semitendinosus and gracilis tendons. Furthermore, combined hamstring muscle volumes on the surgical side were reduced by 12%, although 7% larger volume was observed in the surgical limb for the biceps femoris muscle. The difference in volume, peak cross-sectional area (CSA) and length of the semitendinosus and gracilis correlated significantly with the deficit in knee flexion strength. To the authors’ knowledge, no previous research has assessed muscle morphology in donor site muscles or compared functional outcomes between single and double hamstring tendon graft methods following ACLR in paediatric patients.

**Aims and hypotheses**

There is currently no clear indication in the literature regarding a single or double hamstring tendon (single bundle) autograft for ACLR in the paediatric patient. The primary aim of this single blind randomised controlled trial is to determine whether a single tendon, single bundle ACLR or a double tendon, single bundle ACLR leads to superior clinical outcomes postsurgery in paediatric patients with ACL injury. Primary outcome measures will include graft failure and side to side difference in graft laxity. Secondary outcome measures will investigate growth disturbance rates, passive and dynamic knee joint function (range, strength), lower limb function (power, agility, stability), muscle and ligament morphology and patient-reported outcomes. The primary timepoint will be 1-year postsurgery and secondary timepoints will be 2-year and 5-year postsurgery. We hypothesise that compared with double hamstring tendon graft ACLR, patients who receive a single hamstring tendon graft ACLR will have reduced rerupture rates and smaller side-to-side laxity deficits.

**METHODS AND ANALYSES**

**Study design and setting**

We will conduct a single-site, prospective, single blind, randomised controlled trial with two parallel treatment arms. The study will be conducted in the Queensland Children’s Hospital (QCH), the only paediatric focused quaternary hospital covering a population of 5 million people. We will offer recruitment to patients enrolled in the Australian Paediatric ACL Injury Registry at the QCH site. Inclusion will start in July 2021 and is expected to finalise in July 2023, which will allow for read-out of the primary endpoint in July 2024. The proposed flow of patients thought the trial is displayed in figure 1.

**Recruitment strategy**

All consecutive patients between the age of 10 and 18 who present to the orthopaedic outpatient’s clinic at the QCH with an isolated ACL±meniscal injury will be provided with a recruitment package during their outpatient appointment. A follow-up phone call will be made to ensure that potential participants received the study information.

**Inclusion and exclusion criteria**

Potential participants will be excluded if they have:

2. Collateral ligament instabilities of grade I or greater (2–5 mm).
4. Combined knee surgery with high tibial osteotomy or medial patellofemoral ligament.
5. Evidence of early knee osteoarthritis on MRI.
6. Previous knee surgery on the affected side.
7. Chronic musculoskeletal conditions.
8. BMI>35.
9. Surgeon recommendation for an extraphyseal technique for ACLR.

**Study procedure**

Potential participants will first be screened against the inclusion criteria in the orthopaedic outpatient clinic at the QCH. Following baseline testing (T1 MRI), eligible participants will be randomised into one of the two surgical groups. The surgeons performing the surgeries will be well versed in both ACLR techniques and will be advised of the patient’s randomised surgical technique just prior to the surgery and will proceed accordingly.

**Patient and public involvement**

Patients were not involved
► In the development of the research question.
► In the decision of the outcome measures.
► In the study design.
► In the recruitment to and conduct of the study.
► In how the results will be disseminated.

**Surgical techniques**

Two senior surgeons will perform all the randomised ACLR surgeries as detailed below. Both have been allowed a surgical learning curve of 20 cases (minimum) before the start of the trial. So that there is no variability among equipment used, Smith & Nephew (S&N) will be used for the two techniques: single hamstring graft technique will use UltraButton-round ExtendoButton; double hamstring graft technique will use Endobutton-Biosure Regenesorb screw.\(^{35,36}\) Patients who exhibit a pivot-shift of grade 2 or greater following ACLR will be considered for an additional lateral-tenodesis.\(^ {37}\)

**Tendon harvest and graft preparation**

The semitendinosus hamstring tendon alone will be harvested for the single graft technique and the semitendinosus +gracilis hamstring tendons will be harvested for the double graft technique. A tendon stripper will be used to release the tendons from their proximal attachment via a standard push technique to an appropriate length.

Graft preparation for the single hamstring technique will involve tripling the single semitendinosus tendon over two S&N UltraButton loops (with a round ExtendoButton being attached to the tibial UltraButton). Graft preparation for the double hamstring technique will involve doubling the semitendinosus+gracilis tendons over one S&N Endobutton loop. For both methods, the ends of the tendon complex are sutured via a whip-stitch technique using a #1 Ethibond suture on a J-needle. The prepared tendon complex will be set aside and soaked in a Vancomycin laden Raytec sponge and placed into the soft tissue tunnel where the hamstring tendons were harvested.

Once prepared, the graft is measured for both length (to ensure that the graft will adequately span the knee joint and sufficiently pass through both tunnels) and diameter (to determine the required femoral and tibial tunnel diameters for reaming).

**Knee arthroscopy**

The knee arthroscopy is performed using standard lateral and medial portal sites. All compartments of the knee are identified and examined for any additional pathology (chondral injuries, meniscal tears, etc), the notch is identified, and femoral and tibial attachments are identified. The pathological ACL is identified, and its stump or scarred remnant is debrided sufficiently. As much of the tibial stump/footprint is left to allow for optimal tibial tunnel placement and to aid in revascularisation of the graft;\(^ {38,39}\) however, enough is debrided away, so that it does not interfere with passing of the graft or cause impingement. The lateral wall of the notch is cleared with either a shaver or via radiofrequency ablation and prepped with a curette. The fat pad is debrided to allow for adequate visualisation. If any meniscal pathology is identified, it is addressed prior to the ACLR.

![Figure 1](http://bmjopen.bmj.com/)

**Figure 1** Experimental design flowchart according to the Consolidated Standards Of Reporting Trials (CONSORT) statement guidelines. ACL, anterior cruciate ligament; ACLR, ACL reconstruction.
Tunnel drilling
The femoral tunnel is drilled first. Once the notch has been cleared, the optimal position is determined—this is usually 30° lateral from the roof of the notch (11 o’clock in the right knee, 1 o’clock in the left knee) at the point 5 mm anterior to the posterior cortex of the notch. The patient’s knee is positioned into full flexion (normally 120°) to allow for adequate placement of the guide pin at the desired position. The pin is drilled through the femur and pushed through the soft tissues and skin of the anterolateral thigh. The desired position is achieved using an Acufex offset drill guide and is reviewed on scope. In skeletally mature patients, the pin should be directed approximately 30° anteriorly and 30° laterally, with respect to the femoral long axis, however, in the younger patient with open physes the pin is directed as vertical as possible to ensure that the physis and subsequent growth is disrupted as little as possible. With the knee still in full flexion, the femoral tunnel is drilled first with a 4.5 mm drill through the lateral femoral cortex, this tunnel is measured to determine tunnel length, then the preliminary tunnel is reamed to desired diameter as determined by graft measurement.

The tibial tunnel is positioned using an S&N ACUFEX™ drill guide. The tip of the guide is passed through the anteromedial portal and positioned to create a tunnel that enters the joint through the posteromedial portion of the ACL footprint. In the skeletally immature patient, the length and angle of the tunnel may be more variable as the surgeon will target the drill tunnel perpendicular to the growth plate to minimise the likelihood of growth disturbance. A 2.4 mm drill-tipped guide wire is used to establish the line of the tibial tunnel using the jig. Using the positioned guidewire, this tunnel is reamed to desired diameter as determined by graft measurement earlier. The tunnel is again measured.

Both femoral and tibial tunnels are smoothed cleared of any debris using a shaver to allow for smooth graft passage in the subsequent steps. The graft is marked at either end using a sterile marking pen factoring in tunnel lengths and desired graft length spanning the knee joint. A nylon suture is threaded into the slot of a passing pin. The loop of the suture is held externally, the passing pin is drawn into the joint and out through the femur, drawing the free ends of the suture out through the lateral thigh.

Single tendon, single bundle, graft passing and fixation
The nylon suture is pulled through the tibial tunnel, so that the loop end is exiting out of the tibial tunnel. The graft is orientated and the Ethibond sutures are placed through the nylon loop. The Ethibond sutures are passed through the tibial and femoral tunnels and out of the skin of the anterolateral thigh. The arthroscopy is placed into the knee joint and the Ultrabutton loop and graft are pulled into the femoral tunnel under vision to the line drawn on the graft from previous measurements. The Ultrabutton is toggled and flipped on the femoral side. The graft is held taught and the Femoral Ultraloop is reduced pulling the graft into the femoral tunnel to its desired length (~20 mm). The knee is then brought out to 30–40° flexion, and the tibial Ultraloop is reduced to pull the graft into the tibial tunnel. Final tensioning of the graft is done with knee extended to 0° flexion the ExtendoButton is secured down to the tibia.

Double tendon, single bundle, graft passing and fixation
As above, however, in this case, an Endobutton loop is used as opposed to the Ultrabutton loop. The graft is held taught with the Ethibond suture tails on the tibial side of the graft and, the knee is cycled through flexion/extension a number of times and the knee is then brought out to 20–30° flexion, the assistant is asked to secure the foot as well as place anterior directed force the distal femur. A wire is inserted behind the graft in the tibial tunnel and a Biosure Regenesorb screw is fully advanced and secured to fix the graft into the tibial tunnel.

Postoperative care and rehabilitation
The knee is placed in a Richard splint in full extension. In-patient (oral analgesia with option for intramuscular opioid injection) and discharge medication (oral analgesia only) doses as per individual patient requirements. The patient is seen by the physiotherapist day 1 postoperatively for assessment and treatment as per the Children’s Health Queensland ACL Post-operative Rehabilitation Guidelines (online supplemental file 1).

In cases where meniscal repair was concomitantly performed weight-bearing and range of motion (ROM) restrictions are surgeon dependent based on extent and location of repair, but the majority will be non-weight bearing and have ROM restricted for 6 weeks postoperatively. These patients will all be discharged in an ROM brace with increasing ROM allowed over the 6-week period as per surgeon advice. Following 6 weeks, the brace is removed and patients can complete ROM and full weight bearing.

All patients will undergo rehabilitation as per the Children’s Health Queensland ACL Reconstruction Rehabilitation Guidelines for Physiotherapists will be advised to completely abstain from full return to sports for at least 12 months and prior to return, they will be required to meet phase 5 criteria of the Rehabilitation Protocol (online supplemental file 1).

Standard medical imaging protocol
All patients enrolled into the randomised controlled trial obtain the following standardised imaging in accordance with current clinical practices at the QCH.

Preoperative medical imaging:
- Plain X-rays of the affected knee, in both coronal and sagittal projections
- Bilateral anterior–posterior lower limb weight-bearing X-rays to assess leg length and coronal plane alignment (ie, mechanical axis deviation, lateral distal femoral angle, medial proximal tibial angle)
- Wrist or elbow anterior–posterior and lateral X-rays for assessment of patient’s bone age.
- MRI to assess chondral status, menisci status, ACL or graft morphology, growth plate status.

Day 1 postoperative medical imaging:
- Plain X-rays of the affected knee, in both coronal and sagittal projections
1, 2 and 5-year postoperative medical imaging:
- Plain X-rays of the affected knee, in both coronal and sagittal projections
- Bilateral anterior–posterior lower limb weight-bearing X-rays to assess leg length and coronal plane alignment (ie, mechanical axis deviation, lateral distal femoral angle, medial proximal tibial angle).
- MRI to assess chondral status, menisci status, ACL or graft morphology, growth plate disturbance, position of tunnels and hardware.

Study outcome measures

Primary outcomes
1. Passive anterior–posterior knee laxity: side-to-side difference in anterior tibial translation will be measured by a GNRB device attached to the patient’s leg, measuring tibiofemoral displacement by performing an automated Lachman test and obtaining a force–displacement curve. Three measurements will be made on each knee, and the final value will be recorded as per the GNRB guidelines. Anterior–posterior tibiofemoral laxity will be categorised as a ‘low’ side-to-side difference (<3 mm), a ‘moderate’ side-to-side difference (3 to 5 mm) or a ‘severe’ side-to-side difference (>5 mm or ruptured). The manual Lachman test and the pivot-shift test will also be graded according to International Knee Documentation Committee guidelines.
2. Graft failure incidence: the incidence of graft failures will be quantified at T2, T3 and T4. Failure in this study will be defined by a side-to-side difference in anterior–posterior knee laxity >6 mm or a pivot shift ≥grade 2.

Secondary outcomes
1. Growth disturbance incidence and type: in accordance with the previous assessments of growth disturbances, following ACLR, measurements will be recorded at T2, T3 and T4, and limb length will be assessed. A limb length discrepancy or angular malformation will be classified as a difference of 1 cm and/or 3° between the operated and non-operated limbs, respectively.
2. Knee joint ROM: the flexion or extension deficit will be calculated at T1, T2, T3 and T4 by subtracting the respective degrees of the operative knee from those of the contralateral knee.
3. Isokinetic strength evaluation: an isokinetic dynamometer (Humac NORM, Massachusetts) will be used to evaluate knee flexion/extension concentric strength as well as internal/external tibial rotation concentric strength on both the surgical and contralateral lower limbs. For knee flexion strength measurements, participants will be seated with their pelvis, chest and thigh stabilised using Velcro straps, their hip flexion angle set at 90 degrees and their ankle flail and held in place above the malleoli to the Humac NORM shank with a Velcro strap. At T1, flexion/extension isokinetic concentric strength tests will be performed at an angular velocity of 60 deg/s through the patient’s available knee flexion ROM and isometrically at standardised angles within the patient available knee flexion ROM. At T2, T3 and T4, repeat T1 knee flexion/extension assessment at 60 and 180°/s and additionally perform knee internal/external rotation isokinetic concentric strength tests at 60 and 180°/s, across an ROM between each participant’s maximum comfortable internal/external rotation limits. Testing will be performed on both the non-operative and operative limbs, with the order of limb tested randomised to negate any fatigue effects. In addition to individual peak strength measurements, agonist/antagonist strength ratios will be calculated using the peak strengths for flexion/extension and internal/external tibial rotation.
4. Muscle-tendon morphology and quality: in addition to the standardised imaging protocol for ACL patients at the QCH, additional medical imaging protocols will be performed at T1, T2, T3 and T4 MRI scans. The three-dimensional graft structures will be segmented in Mimics Research 20.0 (Materialise, Belgium) from each participant’s MRI scan. Graft structure and morphology will be assessed for CSA and integrity, both within the tunnels and spanning the knee joint.
5. Graft morphology: a paediatric-trained radiologist consultant will be reviewing and reporting on the T2, T3 and T4 MRI scans. The three-dimensional graft structures will be segmented in Mimics Research 20.0 (Materialise, Belgium) from each participant’s MRI scan. Graft structure and morphology will be assessed for CSA and integrity, both within the tunnels and spanning the knee joint.
6. Patient-reported outcome measures: patient-reported outcome measures will be collected at T1, T2, T3 and T4 and will include the Pedi-IKDC (paediatric international knee document committee), HSS Pedi-FABS (hospital for special surgery paediatric functional activity brief scale) and Paediatric KOOS (knee injury and osteoarthritis outcome score).
7. Physical/functional outcome measures will be collected at T2, T3 and T4 and will include: (1) Y-balance test, (2) forward step-down test, (3) double jump for distance, (4) vertical jump for height, (5) single hop for distance, (6) cross-over hop for distance.
8. Postoperative pain: the patient/family will be required to complete pain diaries and record medication usage for the first 2 weeks after the surgery.

Sample size determination

Our sample size calculations are based on a three-level outcome variable comparing anterior-posterior tibiofemoral laxity in the reconstructed and unaffected knee (‘low’ side-to-side difference (<3 mm), ‘moderate’ side-to-side difference (3 to 5 mm) or ‘severe’ side-to-side difference (>5 mm or ruptured) as differences of this magnitude were considered to be clinically important. Pilot data
from our hospitals’ perspective ACL injury registry classified 74% as low, 7% as moderate and 19% as severe or rupture, and we assume that these percentages will hold in our single hamstring tendon graft ACLR group. We expect that in the experimental arm, the equivalent probabilities will be 93%, 2% and 5%. This is equivalent to specifying a proportional OR of 0.07. With alpha=0.05 and power=80%, we are required to record outcome data on 43 participants in each group to detect a between-group difference of this size or greater. To increase the power of the study and allow the maximal tolerated level of dropout at T2, 100 patients will be randomised.

**Randomisation**

Participants will be randomly allocated by the Griffith University randomisation service to the single hamstring tendon graft ACLR group or the double hamstring tendon graft ACLR intervention group. Participants will be stratified according to skeletal maturity and sex to minimise confounding bias and a randomly varied block size will be used to ensure participants are more evenly allocated throughout the entire trial. The Griffith University randomisation service will conceal group allocation from the study investigators until the participant has been enrolled and baseline data have been collected.

**Blinding**

To minimise ascertainment-bias, this trial is single-blinded, where patients are blinded to surgical technique. External entry points for surgery are equivalent for both surgical techniques and, therefore, patients will not be able to guess group allocation. Due to the nature of the intervention, the treating surgeons cannot be blinded to group allocation. Furthermore, it is not feasible to blind the postoperative management team as surgical notes will be reviewed prior to follow-up appointments.

**Data management**

The percentage of eligible participants successfully recruited, and numbers of eligible who choose not to participate will be recorded along with their age and sex. Participant retention will be recorded throughout the trial period. Paper documents and files will be deidentified, labelled with a participant identification code and stored in a locked filing cabinet. Consent forms and demographic information will be kept separately, also in a locked filing cabinet. The list of participant identification codes and all other electronic data will be stored securely through a Research Electronic Data Capture database (https://www.project-redcap.org/software/) on a secured network accessible only to the registered members of study team.

**Statistical analysis plan**

Standard principles for RCTs will be followed, and primary analyses will be conducted using between-group comparisons on all participants on an intention-to-treat basis. There is a small risk that the surgeon may deem a harvested hamstring tendon inadequate for a single tendon graft (see safety consideration below) and, therefore, need to break randomisation. To account for this potential, a secondary, per-protocol analysis will be used to assess the effect of treatment received and models will be adjusted for potentially confounding variables if necessary. The primary timepoint will be after 1 year, and the primary comparison will be the quantitative anterior-posterior laxity results between the two surgical techniques. Effect of surgical technique will be assessed using ordinal logistic regression with technique (single/double) included as the main effect. To determine between-group differences at 2 and 5 years postsurgery, we will employ mixed effects ordinal logistic regression models with patient included as a random effect, and time (1, 2 and 5 years) and surgical technique included as main effects and a time-by-technique interaction included as fixed effects. For continuous outcomes, comparison will be by linear regression models. Where continuous data do not meet linearity assumptions, as assessed by inspection of boxplots and the Shapiro-Wilks test, it will be assessed using non-parametric methods such as median regression. For dichotomous outcomes, comparison will be by logistic regression models. For count outcomes, comparison will be by Poisson regression models. Significance will be accepted at p<0.05. Sensitivity analyses to assess the effect of missing data will be undertaken on an outcome-by-outcome basis using MAR (multiple imputation) or NMAR (using pattern-mixture models) according to the pattern of the missing data.

**Cost-utility analysis**

Utility values will be obtained from the EQ-50 (with a 1-week recall) at baseline (T1), and 1-year, 2-year and 5-year postsurgery and will be transformed into Quality of life-adjusted years with means and variances. The health economic evaluation will be determined using the incremental cost-utility ratio. Resource utilisation will be determined from hospital finance reports related to the initial stay in hospital and using a patient (or parent) administered case report form that documents information on patient and caregiver demographics, educational and employment information, usage of health resources (ie, visits to general practitioners, physiotherapists, emergency department, patient expenses related to medication and out-of-pocket transportation costs to receive additional medical care, patient or caregiver days off work) using a health resource utilisation questionnaire. Furthermore, the following health service utilisation data will be collected:

- Details of hospital admissions, outpatient episodes and emergency department presentations including episode, clinical, demographic and costing information (such as diagnosis, procedures, length of stay, cost of encounter, etc) for the duration of the study and 12 months prior to consenting—from routinely collected hospital and emergency department administrative data.
Safety, adverse events and complications

Surgical treatment and clinical follow-up will be conducted in accordance with current clinical practices for the participating surgeons at the QCH. Intraoperatively, if a harvested hamstring tendon is deemed to be inadequate (ie, <6 mm in diameter and/or of poor quality) the decision may need to be made to convert from the single to the double hamstring graft technique. Presence of meniscus injuries, defined by the necessity to repair or partially resect tissue due to meniscus instability, will be determined during ACLR. Any adverse events occurring during preoperative and follow-up testing sessions will be recorded on an Excel spreadsheet. Minor adverse events are classified as muscle soreness, muscular fatigue or mild injuries that do not require medical attention. Major adverse events are conditions that require medical attention, such as a fracture, equipment failure or infection and would likely result in the child discontinuing the testing session. All adverse events, regardless of their severity, will be documented and reported to a senior study advisor and if serious, escalated to the ethics committee with information reported to the child’s treating physician as necessary. Risk assessments, including strategies to minimise adverse events, will be completed prior to participation in the testing session. For all onsite testing, participants will be directly supervised by an investigator who is trained to deliver first aid and CPR. Postoperative complications (ie, thrombosis, infection, rupture) will be recorded. A data monitoring committee will convene every 6 months to monitor patient safety and treatment efficacy during the surgical stage of the trial. The DSMB membership comprising a Chair, Medical Monitor and Secretary, will be independent to the trial and will not participate as investigators of the trial or have any financial, scientific or other conflict of interest with the trial.

Ethics and dissemination

Full ethical approval for this study has been obtained by the Children’s Health Queensland Human Research Ethics committee (HREC/21/QCHQ/73043, Protocol V2.1 29072021). The study will be conducted in agreement with the Helsinki declaration. Written and informed parent/guardian consent will be obtained prior to study enrolment by the study investigator. Verbal assent will be obtained from children under the age of 12 years and written assent will be obtained from children who are 12 years and older. This trial is registered with the Australian New Zealand Clinical Trials Registry and the study protocol is reported according to the Standard Protocol Items; Recommendations for Interventional Trials statement13 (see Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist online supplemental file 2). Changes to the study protocol will be communicated to the ethics committee and updated on the trial registry. The primary study results will be submitted for publication to an international, peer-reviewed journal and disseminated to participants and healthcare professionals via newsletters and conference presentations.

DISCUSSION

This study protocol describes a prospective randomised controlled trial design to determine whether a single or double hamstring tendon graft ACLR leads to superior clinical outcomes at 1, 2 and 5-year postsurgery in skeletally immature patients with ACL injury. The International Olympic Committee (IOC) has advocated for further research with regards to efficacy of graft choice and different surgical reconstruction techniques.13 We aim to add to the current knowledge putting to test these two reconstruction techniques with long-term clinical follow-up and imaging. To our knowledge, this will be the first RCT study to investigate two different randomised ACLR techniques in the skeletally immature patient with standardised rehabilitation protocols, clinical follow-up and postoperative imaging to track the patient’s progress and assess graft and intra-articular integrity.

The surgical procedures have been selected based on commonly used reconstruction techniques using hamstring autograft for the skeletally immature patient. The difficulty is that within the literature or among surgeons that there is no true consensus for which has better long-term results with regard to both graft longevity and patient recovery postsurgery.40 The literature supports other graft choices in adults such as quadriceps tendon or patella tendon;52 53 however, the paediatric literature remains scarce. At present, hamstring autograft is the most common technique used to reconstruct the ACL in the skeletally immature patient. As with all injuries, options exist for both operative and non-operative treatment of ACL injuries in the paediatric population; however, the literature supports early reconstruction to avoid the potential consequences of arthritis and consequent chondral and meniscal pathology.13

Primary outcome measures will include graft failure and graft laxity. Secondary outcome measures will investigate growth disturbance rates, passive and dynamic knee joint function (range, strength), lower limb function (power, agility, stability), muscle and ligament morphology and patient-reported outcomes at 1, 2 and 5-year postsurgery. Children with open or closed physes and children of differing sex are likely to respond differently to the intervention. For this reason, we will stratify randomisation enable equal distributions across intervention groups. Children with meniscal tears at baseline may be managed differently, and, for this reason, results may also be stratified on this basis.

A limitation of this study is that our follow-up at present is set for 5 years postsurgery—the IOC has suggested that follow-up goes as long as 10 years so that long-term
knee-health and quality of life can be captured. A second limitation is that we are comparing surgical techniques and using only one type of autograft; it could be beneficial, given the acceptance of alternative graft choices in adults, to compare different graft choices in the paediatric population.

Author affiliations
1Department of Orthopaedics, Children’s Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia
2Griffith Centre of Biomedical and Rehabilitation Engineering, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
3Department of Medical Imaging and Nuclear Medicine, Children’s Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia
4Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia
5Centre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia

Twitter Tristan Reddan @tristanreddan
Contributors DB was key in study design and reading/approving the final draft of the manuscript. GM was involved in study design, was a major contributor in writing the manuscript, and reading/approving the final draft of the manuscript. LJ was involved in study design and reading/approving the final draft of the manuscript. KB was involved in study design, finalising the physiotherapy protocol, and in writing the manuscript. TR, CS and KF were involved with study design and the medical imaging protocols for the study. TP and DS were involved with study design, protocol preparation for isokinetic strength testing and manuscript preparation. RSW was involved with study design, sample size determination and statistical analysis plan. JB contributed to the design of the cost-utility analysis and the associated requests for patient health record data. CPC coordinated the study protocol development, ethics and governance approvals, trial registration and was a major contributor in writing and approving the final manuscript.

Funding This is an investigator-initiated project that has funding support from Smith & Nephew Orthopaedics Ltd.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This project has been approved by the Children’s Health Queensland Hospital and Health Service Human Research Ethics Committee (HREC/21/CHQ/73043).

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Garrett Malayko http://orcid.org/0000-0003-2289-6744
Tristan Reddan http://orcid.org/0000-0003-1843-1602
Robert S Ware http://orcid.org/0000-0002-6129-6736

REFERENCES


GUIDELINE

ACL Reconstruction Rehabilitation Guidelines for Physiotherapists

Children’s Health Queensland

Purpose

These rehabilitation recommendations are a guide for clinicians treating paediatric and adolescent patients who have undergone an anterior cruciate ligament (ACL) reconstruction.

Related documents

Procedures, Guidelines, Protocols

- CHQ-WI-65671-Post-Operative Management and Patient Flow of Patients Following ACL Reconstruction
- CHQ ACL Reconstruction Rehabilitation Guidelines for Patients

Guideline

Rates of ACL re-rupture are much higher in the paediatric population (Clare L Ardern et al., 2018), so additional caution is required in the management of this patient group. Ensure sound clinical reasoning is used and only progress your patient when you feel confident in their ability.

General Guidelines:

- Rehabilitation in this population is slower than in adults.
- Rehabilitation includes five phases and continues for 12 months following surgery.
• Exercise bike can commence at three months.
• Swimming with a pool buoy can commence at four months and progress to kicking at five months.
• Swimming with flippers can commence at six months.
• Running in a straight line can commence at four-six months.
• Return to sport is not recommended before 12 months.

Do
• Ensure to individualise each patient’s program based on surgeon’s recommendations.
  – Meniscal repairs will have period of Non-Weight Bearing (NWB) (generally six weeks post-op) and therefore be behind standard milestones.
  – Slow to progress or non-compliant patients should be encouraged but not progressed beyond where they are capable, irrespective of amount of time post-op.
  – Over-enthusiastic/impatient patients may require additional counselling to avoid them returning to dynamic activities and sports prematurely.
• Encourage swelling and pain management initially; this will impact the longer-term rehabilitation outcomes.
• Give patients and parents advanced knowledge of length and expectations of the rehabilitation; this should be part of the informed consent process.
• Aim to see the patient regularly in the first six months and at least monthly thereafter.
• Contact surgeon or LCCH Physiotherapy Department with any concerns, queries or difficulties

Don’t
• Discharge the patient to progress on their own prior to 12 months. If you cannot provide this level of service, please refer back to CHQ.
• Progress the patient based purely on the protocol. If the knee is not stable or strong enough for an activity, utilise extra exercise/therapy to achieve this.
• Commence open chain weighted exercises.
The Five Phases of ACL Rehabilitation

Phase 1
Recovering after surgery
(0-2 weeks)

Phase 2
Getting stronger by retraining the body and the brain
(2 weeks - 4/6 months)

Phase 3
Create a platform for running, agility and landing
(4/6 - 9 months)

Phase 4
Practise sports related skills
(9-12 months)

Phase 5
Return to sport and prevent re-injury
(> 12 months)
Knee extension/Richards splint to be worn at all times in these initial two weeks. Depending on surgeon preference the brace may be straight or bent to 30°, either way exercises are to be performed on top of the brace.

Patient allowed to WBAT (if no meniscal repair) but advise crutch use until two-week post-op review.

Dressings can be debulked Day 1 prior to discharge depending on wound ooze. Replace dressings with double layer Tubigrip®.

In this phase, the emphasis should be on swelling control and normalising gait with crutches.

**Exercise suggestions**

- static quads
- static hamstrings
- co-contractions quads/hamstrings
- glute squeezes
- heel slides

**Outcome measures to guide progression to Phase 2**

<table>
<thead>
<tr>
<th>Patient outcomes at 2 weeks</th>
<th>Physiotherapist review at 2 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>↓↓swelling</td>
<td>stroke test (Sturgill, Snyder-Mackler, Manal, &amp; Axe, 2009) 0 - 1+</td>
</tr>
<tr>
<td>straight knee</td>
<td>knee extension = 0°</td>
</tr>
<tr>
<td>knee flexion ≥ 90°</td>
<td>knee flexion = 90-100°</td>
</tr>
<tr>
<td></td>
<td>quadriceps lag test = 0° to 5°</td>
</tr>
</tbody>
</table>

(Cooper, 2015)
The graft is at its weakest 6-10 weeks post-op (C. L. Ardern, Webster, Taylor, & Feller, 2011). It is particularly important during this period that the patient adheres to recommended guidelines.

**Exercise suggestions**

<table>
<thead>
<tr>
<th><strong>Range of motion</strong></th>
<th><strong>Manual therapy</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• heel slides</td>
<td>• patello-femoral mobilisations</td>
</tr>
<tr>
<td>• prone assisted knee bend stretches</td>
<td></td>
</tr>
<tr>
<td>• prone knee hangs</td>
<td></td>
</tr>
<tr>
<td>• hamstring and calf stretches</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Cardiovascular exercises</strong></th>
<th><strong>Strength</strong></th>
</tr>
</thead>
</table>
| • gentle hydrotherapy; exercise in the pool is optional once surgical wounds have healed. This may comprise of walking in water, mini squats, calf raises, lunges, and stretches. | • VMO activation  
• co-contractions of quads/hamstrings in isolation and with weight bearing exercises  
• bridging  
• calf raises (bilateral progressing to unilateral)  
• wall sits  
• step ups  
• hamstring wobbles  
• hamstring curls (unresisted)  
• mini squats → progressed as able  
• mini lunges → progressed as able |

**DO NOT commence swimming**

<table>
<thead>
<tr>
<th><strong>Outcome measures to guide progression to Later Phase 2</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• no knee joint effusion</td>
</tr>
<tr>
<td>• knee flexion 125+ degrees, still maintain full knee extension</td>
</tr>
<tr>
<td>• calf raises 10x minimal support, knee fully extended</td>
</tr>
<tr>
<td>• balance testing Able to hold terminal knee extension during single leg stance</td>
</tr>
</tbody>
</table>
### Exercise suggestions

#### Strength

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Exercises</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 weeks</td>
<td>• step ups/downs</td>
</tr>
<tr>
<td></td>
<td>• seated knee curls with TheraBand®</td>
</tr>
<tr>
<td></td>
<td>• squats and lunges with light weights</td>
</tr>
<tr>
<td></td>
<td>• single leg squats</td>
</tr>
<tr>
<td></td>
<td>• eccentric hamstring drills</td>
</tr>
<tr>
<td></td>
<td>• core stability exercises</td>
</tr>
<tr>
<td>8 weeks (aim for full range of motion)</td>
<td>• increase depth squats/lunges</td>
</tr>
<tr>
<td></td>
<td>• over edge of bed flicks and wobbles</td>
</tr>
<tr>
<td></td>
<td>• chair bridging (bilateral)</td>
</tr>
<tr>
<td>10-12 weeks</td>
<td>• split squats</td>
</tr>
<tr>
<td></td>
<td>• walking lunges and weight</td>
</tr>
<tr>
<td></td>
<td>• lower limb stretches</td>
</tr>
</tbody>
</table>

#### Gym program

- leg press (avoid resisted knee extension exercises - this loads the graft)
- incline leg press
- seated hamstring curls → prone hamstring curls

#### Gym program guidelines

(Lloyd et al., 2014)

- should be always supervised to ensure correct technique
- remember equipment is designed for adult sizes and have weight increments that can be too large for younger adolescents. Free weights are preferable in this situation.
- explosive and rapid lifting of weights is **not recommended**
- strength-training for adolescents should begin with low-resistance exercises until proper technique is perfected. When 8 to 15 repetitions can be performed, it is reasonable to add weight in 10% increments.
- for strength gains workouts need to be at least 20 to 30 minutes long, take place 2 to 3 times per week, and continue to add weight or repetitions as strength improves.

---

### Balance and proprioception

- Single Leg Stance (SLS), wobble board etc
- flicks and wobbles
- single leg rebounder balance

### Cardiovascular exercises

- exercise bike with increasing resistance (after 3 months)
- pool running with vest or flotation belt
- CV training- intervals
- rower
- stepper/versa-climber (90’ only, not meniscal repairs)

---

(Cooper, 2015)
Outcome measures to guide progression to Phase 3

<table>
<thead>
<tr>
<th>Measure</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>single leg bridge test (repetitions)</td>
<td>80% of other leg</td>
</tr>
<tr>
<td>single leg calf raises on a step (repetitions)</td>
<td>80% of the other leg</td>
</tr>
<tr>
<td>side bridge endurance test (side plank) (hold time)</td>
<td>80% of other leg</td>
</tr>
<tr>
<td><strong>Functional alignment test</strong></td>
<td></td>
</tr>
<tr>
<td>single leg squat test- 5x squats on 20cm step with crossed arms</td>
<td>Can be rated ‘good’, ‘fair’, ‘poor’</td>
</tr>
<tr>
<td><strong>Unipedal stance test</strong></td>
<td></td>
</tr>
<tr>
<td>SLS with other leg raised and arms crossed</td>
<td></td>
</tr>
<tr>
<td>Eyes open = 43 seconds</td>
<td></td>
</tr>
<tr>
<td>Eyes closed = 9 seconds</td>
<td></td>
</tr>
</tbody>
</table>

Returning to running is often one of the patient’s greatest goals, however it embodies a high-risk. Rehabilitation must be thorough, and individualised to the child’s physiological and psychological maturity to achieve successful outcomes. Emphasise exercises that facilitate dynamic lower limb alignment and biomechanically sound movement patterns and don’t be afraid to slow children down if you do not think they are meeting milestones.

Exercise suggestions

**Continued from previous**
Continue with lower limb strengthening and core exercises:
- walking lunges and weight
- clock lunges
- single leg squats, progress to weighted
- hamstring curls (TheraBand or weights)
- single leg bridging-on ball pluhamstring curls
- forward and side planks

**Balance and proprioception**
- rebounder jogs and stops (two pillows at home)
<table>
<thead>
<tr>
<th>Agility and plyometric exercises</th>
<th>Pool program</th>
</tr>
</thead>
<tbody>
<tr>
<td>• jumping on spot</td>
<td>• can start freestyle with pool buoy at 3 months, kicking with freestyle at 4 months and then progress to kicking with flippers at 6 months</td>
</tr>
<tr>
<td>• jumping forwards/backwards</td>
<td></td>
</tr>
<tr>
<td>• jumping side-to-side</td>
<td></td>
</tr>
<tr>
<td><strong>Progress to</strong></td>
<td></td>
</tr>
<tr>
<td>• 90 degree turns</td>
<td></td>
</tr>
<tr>
<td>• hopping drills (jump-stop, hop-stop, from 10cm to 20cm etc)</td>
<td></td>
</tr>
<tr>
<td>• obstacle hopping, grid hopping</td>
<td></td>
</tr>
<tr>
<td>• step running</td>
<td></td>
</tr>
<tr>
<td>• ladder running</td>
<td></td>
</tr>
<tr>
<td>• box jumps</td>
<td></td>
</tr>
<tr>
<td><strong>Progress to</strong></td>
<td></td>
</tr>
<tr>
<td>• single leg landings with perturbations</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Running type activities</th>
<th>Cardiovascular exercises</th>
</tr>
</thead>
<tbody>
<tr>
<td>• running on mini tramp</td>
<td>• as before plus bike work with cleats can be introduced on a wind trainer</td>
</tr>
<tr>
<td><strong>Progress to</strong></td>
<td></td>
</tr>
<tr>
<td>• running in clinic towards mirror</td>
<td></td>
</tr>
<tr>
<td><strong>Progress to</strong></td>
<td></td>
</tr>
<tr>
<td>• treadmill running</td>
<td></td>
</tr>
<tr>
<td><strong>Progress to</strong></td>
<td></td>
</tr>
<tr>
<td>• field jogging in combination with walking (i.e. walk 30m, jog 30m)</td>
<td></td>
</tr>
<tr>
<td>• gradually increase jog component once have confidence in straight line</td>
<td></td>
</tr>
<tr>
<td>• progress speed</td>
<td></td>
</tr>
<tr>
<td>• progress surface/incline</td>
<td></td>
</tr>
<tr>
<td>• progress to shuttle runs</td>
<td></td>
</tr>
</tbody>
</table>

(Cooper, 2015)
### Outcome measures to guide progression to Phase 4

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Progression Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Single leg bridge test (repetitions)</strong></td>
<td>90% of the opposite leg</td>
</tr>
<tr>
<td><strong>Single leg calf raises on a step (repetitions)</strong></td>
<td>90% of the opposite leg</td>
</tr>
<tr>
<td><strong>Side bridge endurance test (side plank) (hold time)</strong></td>
<td>90% of the opposite leg</td>
</tr>
<tr>
<td><strong>Single leg press (if doing gym program) 1 Repetition-Maximum (1RM)</strong></td>
<td>90% of the opposite leg</td>
</tr>
</tbody>
</table>

**Single hop test**

Subjects stand on one leg and hop as far as possible and land on the same leg. Two valid hops are performed. A limb symmetry index is calculated by dividing the mean distance in cm of the involved limb by the mean distance of the non-involved limb then multiplying by 100.

**Triple cross over hop test**

The test is performed over a 15cm-wide and 6-metre-long marking strip on floor. Patients are required to hop three consecutive times on one foot, crossing the strip on each hop. The total distance is measured. Two valid hops are performed. A limb symmetry index is calculated by dividing the mean distance in cm of the involved limb by the mean distance of the non-involved limb then multiplying by 100.

**Modified landing error score system (less)**

Subjects jump off a 30cm box onto the ground at a distance which is 50% of their height. They then immediately jump vertically as high as possible. The patient performs these multiple times until assessor has observed and marked all of the criteria.

**Y-balance test**

This is performed in anterior, posterolateral and posteromedial directions. The patient stands with one leg in the middle and hands on hips. A composite score for all 3 directions is obtained for each leg. A limb symmetry index is calculated by dividing the mean distance in cm of the involved limb by the mean distance of the non-involved limb and then multiplying by 100.
Dynamic, multi-joint neuromuscular control is the primary focus of ACL rehabilitation in children and adolescents. Phase 4 is important to developing the necessary control and awareness for effective return to sport in stage 5 with appropriate and safe technique. This may mean allowing the child to return to training with specific guidelines, therefore maintaining the social benefits of remaining involved with the team. Providing modified restrictions to the coach or school teacher, ensuring the patient has excellent insight and recruiting the parent/guardian as an active participant can minimise the risks associated with this.

**Exercise suggestions**

- hopping and jump drills continue
- figure 8 running
- diagonal running
- change of direction drills
- slalom running
- sport specific drills and skills (from 26 weeks +) from restricted to unrestricted with game play
- sport specific cardiovascular training

(Cooper, 2015)

**Outcome measures to guide progression to Phase 5**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>hop tests (as previously described in Phase 3)</td>
<td>&gt;90%</td>
</tr>
<tr>
<td>muscle strength tests</td>
<td>90% symmetry</td>
</tr>
<tr>
<td>performed gradual increase in sport-specific training without pain and swelling</td>
<td></td>
</tr>
<tr>
<td>confidence in knee function and psychological readiness to return to sport</td>
<td>&gt;80%</td>
</tr>
<tr>
<td>knowledge of high injury risk knee position and ability to maintain low-risk knee positioning in advanced sport specific actions.</td>
<td></td>
</tr>
</tbody>
</table>
Phase 5
Return to sport and prevent re-injury
(12 months and onwards)

At 12 months post-surgery the patient will be reviewed at LCCH orthopaedic by their surgeon and a physiotherapist. Final outcome measures will be taken and, all going well, return to sport clearance provided.

Data from international registries shows that children/adolescents are much more prone to secondary ACL rupture, including the contralateral leg. According to the 2018 Olympic Committee Paediatric ACL consensus Statement, a comprehensive injury prevention program, emphasising biomechanical alignment and landing/cutting technique should be integrated for all paediatric ACL patients post rehabilitation.

Prevention programs should
- incorporate plyometric, balance, strengthening exercises and education/feedback on proper technique.
- be performed more than once/week
- last greater than 6 weeks
- also include other items such fitness and warm up

Examples
- PEP program: 15-minute training session that replaces the traditional warm up in soccer players
- FIFA 11+ - Soccer
- Netball KNEE Program (Netball Australia)
- KIPP (Knee Injury Prevention Program) for high school basketball and soccer players
- Footy First: for AFL players (+18 years)

Links
- PEP (Prevent injury and Enhance Performance) Program
- FIFA 11+
- Netball Knee Program
- KIPP (Knee Injury Prevention Program
- Footy First (AFL)

Consultation

Key stakeholders who reviewed this version:
- Linda Camilleri (Physiotherapist- Advanced, QCH)
- Dr David Bade (Director of Orthopaedics, QCH)
- Kylie Bradford (Orthopaedic Physiotherapy Clinical Lead, QCH)
- Natasha Weaver (Physiotherapist, QCH)
References and suggested reading


Audit/evaluation strategy

<table>
<thead>
<tr>
<th>Level of risk</th>
<th>Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategy</td>
<td>Audit Protocol Bi-yearly</td>
</tr>
<tr>
<td>Audit/review tool(s) attached</td>
<td>N/A</td>
</tr>
<tr>
<td>Audit/Review date</td>
<td>October 2020</td>
</tr>
<tr>
<td>Review responsibility</td>
<td>HP5 Advanced OPSC MSK Physiotherapist</td>
</tr>
</tbody>
</table>
Guideline revision and approval history

<table>
<thead>
<tr>
<th>Version No.</th>
<th>Modified by</th>
<th>Amendments authorised by</th>
<th>Approved by</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Advanced Physiotherapist</td>
<td>A/Divisional Director, Clinical Support</td>
<td>Executive Directors, Clinical Services (LCCH)</td>
</tr>
</tbody>
</table>

Keywords

Paediatric, ACL reconstruction, rehabilitation, physiotherapy, 65031

Accreditation references

NSQHS Standards (1-10): 1, 2, 6
Appendix 1 - Outcome Measures

- Modified Landing Error Score System (LESS)

Appendix 2 - Preventative Programs

- PEP (Prevent injury and Enhance Performance) Program
- FIFA 11+
- Netball Knee Program
- KIPP (Knee Injury Prevention Program)
- Footy First (AFL)
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>Supplied with trial registration</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>11</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>13</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>10</td>
</tr>
</tbody>
</table>
### Introduction

**Background and rationale**

- 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention: 2-3
- 6b Explanation for choice of comparators: 3

**Objectives**

- 7 Specific objectives or hypotheses: 3

**Trial design**

- 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory): 4

### Methods: Participants, interventions, and outcomes

**Study setting**

- 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained: 4

**Eligibility criteria**

- 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists): 4

**Interventions**

- 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered: 4-7
- 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease): 10
- 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests): 8-10
- 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial: 10

**Outcomes**

- 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended: 7,8,10

**Participant timeline**

- 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure): 4, Figure 1

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations

Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions

Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions

Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how

17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
<table>
<thead>
<tr>
<th>Section</th>
<th>Code</th>
<th>Description</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data management</td>
<td>19</td>
<td>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol</td>
<td>9</td>
</tr>
<tr>
<td>Statistical methods</td>
<td>20a</td>
<td>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>20b</td>
<td>Methods for any additional analyses (eg, subgroup and adjusted analyses)</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>20c</td>
<td>Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)</td>
<td>9</td>
</tr>
<tr>
<td>Methods: Monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data monitoring</td>
<td>21a</td>
<td>Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td></td>
</tr>
<tr>
<td>Harms</td>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td></td>
</tr>
<tr>
<td>Auditing</td>
<td>23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td>N/A</td>
</tr>
<tr>
<td>Ethics and dissemination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research ethics approval</td>
<td>24</td>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>11</td>
</tr>
<tr>
<td>Protocol amendments</td>
<td>25</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>11</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td>Code</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Consent or assent 26a</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Confidentiality 27</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Declaration of interests 28</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Access to data 29</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>9-10</td>
<td></td>
</tr>
<tr>
<td>Ancillary and post-trial care 30</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Dissemination policy 31a</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Authorship eligibility guidelines and any intended use of professional writers</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

**Appendices**

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent materials 32</td>
<td>Model consent form and other related documentation given to participants and authorised surrogates</td>
<td>Provided with PCIF</td>
</tr>
<tr>
<td>Biological specimens 33</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrightied by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.*